The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen

For Immediate Release

Chicago, IL - April 21, 2016 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Medivation ( MDVN ), Synta ( SNTA ), AbbVie ( ABBV ), Gilead ( GILD ) and Orexigen ( OREX ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Medivation ( MDVN ) is back in the news again this week with AstraZeneca rumored to be interested in acquiring the company. Meanwhile, Synta's ( SNTA ) shares shot up on news regarding the company's merger deal with Madrigal.

Meanwhile, companies like AbbVie ( ABBV ) and Gilead ( GILD ) were present with data at The International Liver Congress.

Recap of the Week's Most Important Stories

1. Once again, acquisition rumors regarding Medivation have surfaced with British drug maker AstraZeneca rumored to be considering a bid for the San Francisco-based company. According to the SundayTimes , sources claim that AstraZeneca has held internal talks but is yet to make a formal offer. AstraZeneca has supposedly been looking at the company for the last 6 months and is contemplating a bid of £7 billion.

This is the second time this month that Medivation has been rumored to be an acquisition target. Earlier this month, it was reported that Medivation had supposedly turned down an offer from Sanofi.

With Xtandi bringing in multi-million dollar sales and being developed for additional indications, Medivation has often been considered an acquisition target.

2. Orexigen ( OREX ) terminated its recently-initiated, multi-year CONVENE cardiovascular outcomes trial (CVOT) on obesity drug, Contrave. The move comes shortly after the company acquired full U.S. rights to the drug from Takeda. This was the second CVOT for the drug with the earlier study being terminated due to the revelation of interim data from that study.

Orexigen said that it intends to make certain changes for the optimization of the Contrave / Mysimba post-marketing requirement studies and remains committed to meeting the FDA's post-marketing requirements for Contrave which include completion of a CVOT with a study report due to the FDA by Jan 2022. The company intends to finalize a revised protocol and will start a new CVOT after discussions with the FDA.

3. Synta's shares shot up with the company announcing that it will be merging with private company Madrigal. The combined company will focus on cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). Earlier, Synta was focused on cancer treatments but the company suffered a setback last year when it decided to terminate a late-stage study on a key pipeline candidate (advanced non-small cell lung cancer) due to futility. Soon thereafter, the company decided to cut down its workforce.

The Madrigal merger will provide Synta with a mid-stage candidate being developed for NASH and other indications (Read more: Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals ).

4. Gilead presented results from many mid-stage and late-stage studies on its experimental pan-genotypic, fixed-dose combination hepatitis C virus (HCV) treatments as well as three investigational agents for the treatment of NASH and primary sclerosing cholangitis (PSC) at The International Liver Congress. The company also presented new data on Harvoni showcasing its use in adolescents.

Meanwhile, detailed 48-week results from two large late-stage studies on once-daily tenofovir alafenamide (TAF) 25 mg for certain types of chronic hepatitis B virus (HBV) infection were also presented. TAF is currently under regulatory review in the U.S., EU and Japan with a response in the U.S. expected by Nov 11 (Read more: Gilead Presents Multiple HCV and HBV Data at Liver Congress ).

5. AbbVie was also present at the meeting with new phase II data on its investigational, once-daily, ribavirin-free, pan-genotypic regimen of ABT-493 and ABT-530 for HCV genotypes 1-6.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDIVATION INC (MDVN): Free Stock Analysis Report

SYNTA PHARMACT (SNTA): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

OREXIGEN THERAP (OREX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More